

Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

University of Texas at Austin Advanced Protein Therapeutics Core Facility

RRID:SCR_023740

Type: Tool

Proper Citation

University of Texas at Austin Advanced Protein Therapeutics Core Facility
(RRID:SCR_023740)

Resource Information

URL: <https://biologics.utexas.edu/research/advanced-protein-therapeutics-core>

Proper Citation: University of Texas at Austin Advanced Protein Therapeutics Core Facility (RRID:SCR_023740)

Description: Core catalyzes translation of scientific discoveries into novel protein cancer therapies. Offers therapeutic antibody and enzyme discovery, engineering, and optimization services.

Abbreviations: APT

Synonyms: UT Austin Advanced Protein Therapeutics Core, The University of Texas at Austin UT Austin Advanced Protein Therapeutics Core

Resource Type: access service resource, core facility, service resource

Keywords: USEDit, ABRF, therapeutic antibody and enzyme discovery, optimization services, protein cancer therapies,

Resource Name: University of Texas at Austin Advanced Protein Therapeutics Core Facility

Resource ID: SCR_023740

Alternate IDs: ABRF_1797

Alternate URLs: <https://coremarketplace.org/?FacilityID=1797&citation=1>

Record Creation Time: 20230630T050224+0000

Record Last Update: 20260905T133437+0000

Ratings and Alerts

No rating or validation information has been found for University of Texas at Austin Advanced Protein Therapeutics Core Facility.

No alerts have been found for University of Texas at Austin Advanced Protein Therapeutics Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Bajgain Y, et al. (2026) Mouse Fc-Fc γ RIV structure guides Fc engineering for cross-species Fc γ R recognition. bioRxiv : the preprint server for biology.

Gadallah MI, et al. (2026) Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry. Chemical science, 17(18), 9108.

Blackman SA, et al. (2026) Antibodies blocking PIGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. The Journal of biological chemistry, 302(6), 111476.

Reddy DR, et al. (2026) CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119113.

Ma MT, et al. (2025) Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma. PNAS nexus, 4(1), pgae556.

Goldsmith JA, et al. (2025) Structural basis for neutralizing antibody binding to pertussis toxin. Proceedings of the National Academy of Sciences of the United States of America, 122(14), e2419457122.

Siles Alvarado N, et al. (2025) SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics. Communications medicine, 5(1), 149.

Qerqez AN, et al. (2025) Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV. Cell reports, 44(12), 116593.

Blackman SA, et al. (2025) Antibodies blocking PIGF or VEGF interactions with the NRP1 receptor mediate anti-proliferative effects. bioRxiv : the preprint server for biology.